Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial compared two treatments for eye inflammation — an investigational drug called LME636 and a steroid eye drop called dexamethasone. A total of 43 people were enrolled (32 in the LME636 group and 11 in the dexamethasone group), though slightly fewer actually received treatment (30 and 9 respectively). The trial measured several things related to eye health, including the level of inflammatory cells in the front of the eye, vision sharpness, fluid pressure inside the eye, and detailed eye examination findings. The reported data shows that by Day 15, 14 out of 30 participants in the LME636 group and 9 out of 9 participants in the dexamethasone group met the trial's definition of a "responder" — meaning their eye inflammation (measured by cell levels in the front of the eye) had reduced by at least two steps from where it started. For vision sharpness, measured by how many letters participants could read on a chart, scores across the visits ranged from around 70 to 75 letters for the LME636 group and around 77 to 79 letters for the dexamethasone group. Eye pressure readings across visits ranged from roughly 14 to 16 mmHg (millimetres of mercury, the unit used to measure eye pressure) for LME636, and roughly 15 to 17 mmHg for dexamethasone. For the detailed eye examinations, the reported data shows that more participants in the LME636 group showed increases (worsening) in certain slit-lamp and fundus (back-of-eye) findings compared with the dexamethasone group, though the specific numbers varied across the different features examined. The reported data also shows that when looking at eye pressure changes from the start of treatment to the last on-treatment check, most participants in both groups fell into the "no change" or small-change categories, with 25 LME636 participants and 8 dexamethasone participants recorded as having no meaningful change; small numbers in each group showed minor increases or decreases. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 2 Uveitis Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You must be willing and able to sign a consent form agreeing to take part in the study.
- You must have been diagnosed with non-infectious acute anterior uveitis (inflammation at the front of the eye not caused by infection) in at least one eye.
- The level of inflammation in the front of your eye must be at a moderate level, rated as "2+" or "3+" on a standard medical scale (confirm with trial site).
- You must be able to communicate clearly with the study team and be willing to follow the study requirements.
- There may be additional requirements set by the study that also apply (confirm with trial site).
Who may not be able to join:
- Women who could become pregnant but are unwilling to use effective birth control methods as set out by the study.
- Your eye inflammation is at the highest severity level ("4+" on the medical scale) or you have a visible collection of pus in the eye (called hypopyon).
- Your eye inflammation started more than 2 weeks before joining the study.
- You have inflammation in the middle or back part of either eye, or throughout the whole eye.
- You are currently taking more than 10 mg per day of the steroid medication prednisone or similar steroid medicines (confirm with trial site for full details).
- You have a history of, or currently have, repeated scratches or open sores on the surface of either eye.
- You have or have had tuberculosis (TB) at any point in your life.
- There may be additional reasons that could prevent you from joining the study (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Primary endpoints
Number of Responders at Day 15; Mean Best Corrected Visual Acuity (BCVA) at Each Visit; Mean Intraocular Pressure (IOP) at Each Visit; Number of Subjects With Increase From Baseline in Slit Lamp Parameters at Any Post-Treatment Visit; Number of Subjects With an Increase From Baseline in Dilated Fundus Parameters at Any Post-Treatment Visit
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.